1. The Organised Community

Clusterbusters: origin and structure

Clusterbusters traces its origin to late 1998, when a man posting under the handle “Flash” on an internet bulletin board reported that LSD had interrupted his usual cluster cycles [PEER-REVIEWED/HISTORICAL]12. Skepticism was the initial community response — sufferers had seen “a hundred scams” — but the claim had a plausible pharmacological basis: indole-ring hallucinogens bind serotonin receptors, and Albert Hofmann had originally investigated LSD partly as a headache/migraine treatment historical1. As reports of psilocybin use with similar results accumulated, a core group of self-described advisors and researchers built a website (“The Treatment of Vascular Headaches with Hallucinogenic Substances”) and ran structured discussion and self-experimentation through 2000–2001 community report1. Concerns about the illegality of LSD and psilocybin for members in sensitive professions led the group to relocate and formalise; Clusterbusters, Inc. was founded in 2002 by Bob Wold, a long-time chronic CH patient, and registered as a US 501(c)(3) non-profit historical345.

Clusterbusters now runs annual patient conferences in the US bringing together patients, caregivers, and headache specialists, and its directors are regularly invited to present at neurology and headache conferences historical15. Its role has been documented in a full-length academic history — Joanna Kempner’s book Psychedelic Outlaws — and in mainstream science press (Nature, 2006) as the origin point of what became a formal psilocybin research agenda at Harvard and Yale historical267. The organisation has since been involved, as a research partner (not merely a subject pool), in projects at Harvard, Yale, McGill, the University of West Georgia, and Hannover Medical School in Germany historical3.

National and language-specific equivalents

OUCH(UK) — the Organisation for the Understanding of Cluster Headache — was founded independently of Clusterbusters, arising from UK patients meeting each other in NHS waiting rooms; it launched in 2001 and became a registered charity in 2002, with roughly 40 founding members and now a forum community exceeding 5,000 historical8910. It is patronised by Professor Peter Goadsby and works with the Royal Free and King’s College Hospitals in London historical8. On the clinical-research side rather than patient-advocacy side, the Danish Headache Center in Copenhagen (Rigshospitalet) has run large patient-derived surveys such as the Danish Cluster Headache Survey, a “real-life treatment” study drawing on structured patient data from a tertiary clinic population peer-reviewed12. A 2026 review in Practical Neurology traces the wider pattern: OUCH itself grew out of the same clusterheadaches.com message board that produced Clusterbusters, with Bob Wold’s 2002 non-profit and the UK charity as parallel, independently-arising responses to the same patient need historical66.

Following up on this chapter’s original open question — how far does organised, data-collecting citizen science extend beyond the Anglophone world? — targeted research across German, Scandinavian, Italian, Japanese, Chinese, and Spanish sources found a sharp divide: one language community runs genuine patient-driven data collection with a peer-reviewed output; the rest have patient-founded advocacy and support bodies, but none currently publishes its own patient-collected dataset.

• German — the strongest example of citizen science outside the Anglophone world. Two distinct efforts exist. First, Clusterkopfschmerz-Radar / CLUE (“Clusterkopfschmerzen erforschen”), running on Germany’s national citizen-science platform mitforschen.org since November 2017, led by Jörg Scheidt at Hochschule Hof’s Institut für Informationssysteme, explicitly frames itself as patients researching their own disease (“die Betroffenen erforschen ihre Krankheit selbst”) and invites participants to submit their own hypotheses about triggers and treatment effectiveness citizen science67. By September 2018 it had logged 113 active participants and 2,960 attacks citizen science68, and its patient-logged attack and medication data underpins a peer-reviewed paper: Drescher, Khouri, Amann, Gaul, Kropp & Scheidt, “Effectiveness of medication in cluster headache,” BMC Neurology 21:174 (2021), open access citizen sciencepeer-reviewed69. Separately, the large German patient body CSG e.V. (clusterkopf.de, ~1,250 members in 2024) acts chiefly as a recruitment engine for academic surveys rather than an independent data publisher — it hosts links to clinician-run projects such as the Kiel “Cluster-Gender” study and a MigräneLiga/Frankfurt survey without posting results on its own site, and its transparency disclosures show €15,281.28 in health-insurer funding for a patient-situation survey citizen science70. A CSG-recruited (but clinician-designed and -published) instrument, the Cluster Headache Scales (DRKS00016502, n=302), appeared in Cephalalgia in 2020 peer-reviewed71. The Austrian site clusterkopfschmerzen.at has separately translated and disseminated the D3 loading protocol into German community report11.
• Scandinavian — organised, but no published patient-collected dataset. Sweden’s Klusterhuvudvärksföreningen ran a 2016–2018 government-funded (Arvsfonden) project mapping, via its own members, where patients actually received CH care — a genuine patient-collected exercise, but one that produced a care-navigation guide rather than a public dataset or paper community report72. Sweden’s more systematic CH data instead sits in a clinician-run national quality register peer-reviewed73. Denmark (Hovedpineforeningen, formed by a 2025 merger; Danmarks Patientforening for Hovedpineramte) and Norway (Hodepine Norge, ~6,500 members, active in 2026 health-policy advocacy) have well-organised patient associations but no identified patient-run CH datasets community report7475.
• Italian — patient-founded and patient-directed, but not data-collecting. O.U.C.H. Italia (grappolaiuto.it) is explicitly patient-founded and patient-governed (“Non è un sito di medici”), confirmed independently by a Università Politecnica delle Marche report describing it as founded and directed by expert patients under president Luca Bonventre since 2002 — but it runs a support forum, not a survey or registry community report76. Published Italian CH survey data instead comes from institutional sources: a Censis survey of 129 patients and an earlier Al.Ce. access-to-care study [PEER-REVIEWED/institutional]77.
• Japanese and Chinese — no patient-run, data-collecting CH community located. Native-language searching found no Japanese CH patient association or patient-run survey equivalent to the Tourette-syndrome patient group model that exists for other conditions in Japan; all located Japanese CH data is clinician- or insurer-generated (e.g. a 21,480-person DeSC claims-linked survey in the Journal of Headache and Pain, 2022) peer-reviewed78. Chinese-language searching likewise found only clinical reference material and hospital case series, with no public patient organisation or dataset — though this is a weaker negative result than for Japanese, since much Chinese peer support activity likely occurs in non-indexable WeChat groups and Baidu Tieba forums that could not be assessed here [unverified/COMMUNITY-REPORT absent]79.
• Spanish — an organisation exists but does not publish its own dataset. CRAES/ACRA (Asociación Cefaleas en Racimo y Primarias España, ~500 members since 2011) states research-promotion as a goal but hosts no named citizen-science project, survey instrument, or results on its own site; it has however participated as a recruitment partner in an international patient study (with Fundación del Cerebro) reporting 72.6% suicidal ideation and roughly 28% chronic CH among respondents community report80.

The honest summary: outside the Anglophone Clusterbusters/OUCH model, only the German CLUE/mitforschen.org project has taken patient-logged data all the way to a peer-reviewed publication. Everywhere else checked, patient advocacy and support infrastructure exists, but the actual citizen-science step — collecting and publishing patient-generated data — has not yet happened, or happens invisibly in non-indexable channels this research could not verify.

Community survey research

The single most important artefact of Clusterbusters-driven citizen science is the Clusterbusters Medication Use Survey, first collected and eventually published as peer-reviewed research in 2015 citizen sciencepeer-reviewed1314. Recruited from CH websites and headache clinics, it captured 496 respondents’ self-reported effectiveness of conventional and alternative treatments, and became the evidentiary basis for at least three further peer-reviewed secondary analyses: one on oxygen versus sumatriptan effectiveness peer-reviewed1516, one a mixed-methods qualitative analysis of free-text patient comments (memorably titled “You will eat shoe polish if you think it would help”) peer-reviewed17, and the underlying dataset for the psychedelics analysis discussed below peer-reviewed13. Separately, Clusterbusters helped fund and publicise the International Cluster Headache Questionnaire, with over 3,000 participants, published in the journal Headache in November 2021 citizen sciencepeer-reviewed18.

Key findings from these citizen-science-originated surveys:

Finding	Evidence tier	Source
High-flow oxygen (>10 L/min) and injectable sumatriptan show comparable efficacy (~81–82% response)	PEER-REVIEWED (secondary analysis of citizen survey)	1516
“Nothing worked” reported by 24.7% of respondents in free-text comments; illicit substances mentioned by 35.5%; vitamins/supplements by 12.2%; coffee by 5.3%; exercise by 4.7%	PEER-REVIEWED (qualitative analysis of citizen survey)	17
Indoleamine hallucinogens rated comparable to or better than most conventional medications for aborting attacks and inducing remission	PEER-REVIEWED (citizen survey)	13